NEW YORK (GenomeWeb News) – Epigenomics today announced that a US Food and Drug Administration panel voted in favor of the company’s Epi proColon colorectal cancer screening test but with concerns.

In a meeting held on Wednesday, the Molecular and Clinical Genetics Panel of FDA's Medical Devices Advisory Committee voted that the benefits of the test outweigh the risk for use in patients "who meet the criteria," Epigenomics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.